港股异动 | 维升药业-B(02561)涨超6% 隆培促生长素本地化生产进一步落实那韦培肽新药申请获FDA受理

智通财经2025-06-16

智通财经APP获悉，维升药业-B(02561)涨超6%，截至发稿，涨6.57%，报53.55港元，成交额1153.37万港元。消息面上，6月9日，维升药业与药明生物宣布，维升药业核心产品隆培促生长素商业化批次的技术转移项目正式落地成都，双方还将在该基地合作建设国内首条双腔冻干制剂生产线，这一创新型药物制剂生产技术能极大地提升药物稳定性及临床使用便捷性。据悉，2023年12月，维升药业与药明生物已就...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2543416623?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-06-16 15:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543416623","market":"fut","top_or_hot":-1,"title":"港股异动 | 维升药业-B(02561)涨超6% 隆培促生长素本地化生产进一步落实 那韦培肽新药申请获FDA受理","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，维升药业-B(02561)涨超6%，截至发稿，涨6.57%，报53.55港元，成交额1153.37万港元。消息面上，6月9日，维升药业与药明生物宣布，维升药业核心产品隆培促生长素商业化批次的技术转移项目正式落地成都，双方还将在该基地合作建设国内首条双腔冻干制剂生产线，这一创新型药物制剂生产技术能极大地提升药物稳定性及临床使用便捷性。据悉，2023年12月，维升药业与药明生物已就...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1305615.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 维升药业-B(02561)涨超6% 隆培促生长素本地化生产进一步落实 那韦培肽新药申请获FDA受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 维升药业-B(02561)涨超6% 隆培促生长素本地化生产进一步落实 那韦培肽新药申请获FDA受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-06-16 15:14 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1305615.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，维升药业-B(02561)涨超6%，截至发稿，涨6.57%，报53.55港元，成交额1153.37万港元。消息面上，6月9日，维升药业与药明生物宣布，维升药业核心产品隆培促生长素商业化批次的技术转移项目正式落地成都，双方还将在该基地合作建设国内首条双腔冻干制剂生产线，这一创新型药物制剂生产技术能极大地提升药物稳定性及临床使用便捷性。据悉，2023年12月，维升药业与药明生物已就...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1305615.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1305615.html","article_id":"2543416623","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543416623","pubTimestamp":1750058044,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"消息面上，6月9日，维升药业与药明生物宣布，维升药业核心产品隆培促生长素商业化批次的技术转移项目正式落地成都，双方还将在该基地合作建设国内首条双腔冻干制剂生产线，这一创新型药物制剂生产技术能极大地提升药物稳定性及临床使用便捷性。据悉，2023年12月，维升药业与药明生物已就隆培促生长素的技术转移首次达成战略合作。维升药业拥有那韦培肽在大中华区的独家开发、生产和商业化权利。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","02561":"维昇药业-B"},"translate_title":"Hong Kong stocks changed Weisheng Pharmaceutical-B (02561) rose more than 6%, the localized production of Longpei somatotropin was further implemented, and the new drug application of navirpetide was accepted by the FDA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02561":1},"content_text":"智通财经APP获悉，维升药业-B(02561)涨超6%，截至发稿，涨6.57%，报53.55港元，成交额1153.37万港元。消息面上，6月9日，维升药业与药明生物宣布，维升药业核心产品隆培促生长素商业化批次的技术转移项目正式落地成都，双方还将在该基地合作建设国内首条双腔冻干制剂生产线，这一创新型药物制剂生产技术能极大地提升药物稳定性及临床使用便捷性。据悉，2023年12月，维升药业与药明生物已就隆培促生长素的技术转移首次达成战略合作。值得关注的是，该产品目前已在美国及欧洲获批上市，预计2025年内在中国获批，计划在2028年将实现本地化商业生产。此外，维升药业合作伙伴Ascendis Pharma A/S近日宣布美国食品药品监督管理局（FDA）已受理其用于治疗软骨发育不全（achondroplasia, ACH）患儿的那韦培肽（navepegritide, TransCon CNP）新药申请（NDA），并给予优先审评资格，同时设定了《处方药使用者付费法案》（PDUFA）规定的完成审评目标日期为 2025年11月30日。维升药业拥有那韦培肽在大中华区的独家开发、生产和商业化权利。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2543416623","isCrawlerRequest":true}

港股异动 | 维升药业-B(02561)涨超6% 隆培促生长素本地化生产进一步落实 那韦培肽新药申请获FDA受理

精彩评论

港股异动 | 维升药业-B(02561)涨超6% 隆培促生长素本地化生产进一步落实那韦培肽新药申请获FDA受理